Every analyst has estimates and the post was intended to spark details and not replies that try to be a '' want-t0-be-message board correctional officer expert about non-pertaining answers.
News being attached ''early approval or alike pathway/ fda reviewing/
keeping the focus with FDA to streamline pathway. " without attacks from many directions help in clear focus .
hep-c sales will be about 500 mil better than last e/r ''or more''
we all know that hep-c will decline one day but that monies will be used to buy other companies and grow...hep-c should be ok for two years before a real decline...
I would sugest that gild buy '' srpt'' and maybe a few others alike.Sarepta has platforms that can grow like crazy ''one day could be worth 10 bil a year in sales.
Look what they did last year on biotech around the same time.they smashed a lot of small caps.
big monies and the government with tax collections.
Sarepta has all and much more than any other drug.
The new guidance takes into consideration increased risk tolerance among some DMD patients involved in trials. Acceptable endpoints may now include functional, cardiac, or respiratory metrics, though the FDA has asserted that the ideal trial design still involves a randomized, placebo-controlled design—even if the placebo-controlled part involves using historical data.
Hope thats the case all the time... ''AA''